Serna Bio
Genetic Medicine with Small Molecules
Y CombinatorWinter 2021ActiveHealthcareTherapeuticsBiotechDrug discovery
What they do
Problem
Many diseases are driven by RNA biology that is difficult or impossible to treat with existing therapeutic modalities.
Solution
Serna Bio develops small-molecule drugs that modulate RNA function to enable new genetic medicines.
Who it's for
Pharmaceutical and biotechnology companies and clinicians/patients who use RNA-targeting therapeutics.
Founders
Rabia Khan
Founder
Currently working on drugging RNA with small molecules. Previously built the ML team at Sensyne Health (UK PLC) // and worked at BenevolentAI. Love working at the intersection of biology / technology / business. Foodie at heart.
Company timeline
- Founded2021
- YC batchWinter 2021
- StatusActive
- Team size5 people
- LocationOntario, CA, USA; Remote
Similar startups
Maze Therapeutics
Translating human genetics insights into a pipeline of novel precisio…
Origami Therapeutics, Inc.
Oral drugs to halt neurodegeneration
Stipple Bio
An "epitomics" platform to define and drug cancer-specific epitopes o…
Reverie Labs
Engineering next-generation, brain-penetrant cancer therapies.
BioAge Labs
Antibiotics work by killing bacteria, stopping infections from runnin…
FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets